public✦ Frontier trackCRISPR Therapeutics

CRISPR Therapeutics edits DNA to cure blood disease with a single treatment

A Swiss gene-editing company that turned CRISPR/Cas9 from lab tool into approved medicine — its one-shot therapy CASGEVY functionally cures sickle-cell disease and beta thalassemia, now cleared for children as young as two.

شركة سويسرية لتحرير الجينات حوّلت كريسبر من أداة مختبرية إلى دواء معتمد: علاجها كاسغيفي يشفي فقر الدم المنجلي والثلاسيميا بجرعة واحدة، وأُجيز للأطفال من عمر سنتين.

Next →
  1. The Bottleneck

    What was broken?

    Sickle-cell disease and beta thalassemia condemn patients to a lifetime of transfusions, crises, and hospital visits — manageable, never curable, because the defect sits in the patient's own DNA.

  2. The Move

    Why it worked

    Was first to carry CRISPR/Cas9 across the finish line: ex-vivo editing of the patient's own stem cells (exa-cel/CASGEVY) proved durable enough for regulators in the US, EU, and UK, creating the world's first approved CRISPR therapy with a pharma giant handling commercialization.

  3. The Trap

    Battle scars

    A one-time cure priced for payers to swallow; slow treatment-center rollout and manufacturing complexity; and a pipeline beyond hemoglobinopathies (in-vivo editing, oncology, diabetes) that must prove the platform is bigger than one product.

The problem

Sickle-cell disease and transfusion-dependent beta thalassemia are written into the patient’s genome: misshapen or missing hemoglobin means chronic pain crises, constant transfusions, and organ damage for life. The only cure was a matched donor stem-cell transplant most patients never get.

How it works

CRISPR Therapeutics, founded in 2013 by Emmanuelle Charpentier (later a Nobel laureate for CRISPR), Shaun Foy, and Rodger Novak and headquartered in Zug, Switzerland, edits the defect away. CASGEVY takes the patient’s own blood stem cells, edits them ex vivo with CRISPR/Cas9 so they produce protective fetal hemoglobin, and reinfuses them — one course, durable effect. The strategic research collaboration with Vertex, running since 2015, carried CASGEVY through approval as the world’s first CRISPR-based therapy. The pipeline now reaches beyond blood disease: in-vivo liver editing (CTX310), the zugo-cel CAR-T in autoimmune disease and lymphomas (with a Lilly clinical-supply collaboration), siRNA programs with Sirius Therapeutics, and diabetes cell therapy.

Pain points

Lifelong transfusion dependence and unpredictable pain crises; donor-transplant scarcity and risk; and for the field, the unsolved leap from ex-vivo cell manipulation to safe editing directly inside the patient.

Business model

Shared CASGEVY economics with Vertex, which runs global development, manufacturing, and commercialization, layered with partnered pipeline programs and wholly owned candidates aimed at repeat approvals.

Challenges

Each cure is a logistical operation — cell collection, editing, conditioning, reinfusion — that only specialized centers can deliver, so uptake speed is the commercial question; meanwhile investors value the company on whether in-vivo editing and oncology programs prove there is a second act.

Funding

  • Raised: public company (Nasdaq: CRSP) — historical raise totals not itemized here (MISSING).
  • Valuation: market pricing moves with CASGEVY uptake and pipeline readouts (MISSING).

Latest — July 2026

The FDA approved expanded use of CASGEVY for people ages 2 years and older with sickle-cell disease or transfusion-dependent beta thalassemia — the first genetic therapy cleared for children that young for both conditions — widening the eligible population for the CRISPR pioneer’s flagship cure.

Similar sparks

⚡️ SERIES C✦ Frontier$50M Series C (Jan 2026)

United Kingdom · 2026-01-12

bit.bio programs stem cells into any human cell type at industrial scale

A Cambridge spinout whose opti-ox gene-engineering platform converts stem cells into consistent, batch-after-batch human cells — selling a 50-product ioCells catalogue to drug makers as an alternative to animal testing.

بالعربي

شركة كامبريدج الناشئة تحوّل الخلايا الجذعية إلى أي نوع من الخلايا البشرية بتقنية أوبتي-أوكس، وتبيع كتالوج آيو سِلز لشركات الأدوية بديلًا عن التجارب على الحيوانات.

  • biotech
  • #frontier
⚡️ PUBLICUS$555.5M IPO (Dec 2020)

Canada · 2026-09-28

AbCellera discovers antibody drugs with an AI-powered engine

A Vancouver clinical-stage biotech that finds and develops antibody medicines — from target to manufactured candidate — for itself and pharma partners, after its Lilly-partnered COVID antibody made it Canada's biggest biotech IPO.

بالعربي

شركة تكنولوجيا حيوية في فانكوفر تكتشف أدوية الأجسام المضادة بمحرك مدعوم بالذكاء الاصطناعي لصالحها وشركائها من شركات الأدوية.

  • biotech
  • #canada
⚡️ LATE-STAGE-PUBLIC

China · 2026-02-26

BeOne Medicines makes targeted blood-cancer drugs that outsell Western rivals

Beijing-founded global oncology biotech behind Brukinsa, a BTK inhibitor for B-cell cancers: $5.3B revenue in 2025, triple-listed in New York, Hong Kong and Shanghai, renamed BeOne after redomiciling to Switzerland in 2025.

بالعربي

شركة أدوية أورام صينية عالمية طوّرت دواء بروكينسا لسرطانات الدم وحققت إيرادات 5.3 مليار دولار في 2025، وأعادت تسمية نفسها بي‌ون بعد انتقال مقرها إلى سويسرا.

  • biotech
  • #biotech
⚡️Spark playbook copied! Go build.